The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature [0.03%]
由COVID-19诱发的典型抗磷脂综合征一例及文献复习
Zong-Fang Ren,Ri-Cheng Xiong,Ling-Ling Wang et al.
Zong-Fang Ren et al.
COVID-19 may induce a state of hypercoagulability, particularly in critically ill patients, for reasons that remain unknown. Numerous studies have identified the presence of antiphospholipid antibodies in patients with COVID-19; however, th...
Correction: The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study [0.03%]
订正：结核分枝杆菌治疗对凝血酶弹性云图测定的血液凝固功能影响：前瞻性队列研究
Hans Johan Niklas Lorentsson,Christina R Clausen,Daniel Faurholt-Jepsen et al.
Hans Johan Niklas Lorentsson et al.
Published Erratum
Thrombosis journal. 2024 Nov 7;22(1):98. DOI:10.1186/s12959-024-00670-z 2024
Correspondence: Cancer incidence and mortality after a first-ever venous thrombosis in northern Sweden [0.03%]
通信：瑞典北部首次发生静脉血栓后癌症的发病率和死亡率
Minh-Hoang Tran,Kim-Huong Truong-Nguyen
Minh-Hoang Tran
We congratulate Hägg et al. on their study investigating cancer incidence and mortality following first-ever venous thromboembolism (VTE), which provides valuable insights into VTE as a potential marker for underlying malignancies. However...
Reply to correspondence: Cancer incidence and mortality after a first-ever venous thrombosis in northern Sweden [0.03%]
来信回复：瑞典北部首次发生静脉血栓后的癌症发病率和死亡率
Lovisa Hägg,Marcus Lind,Magdalena Johansson
Lovisa Hägg
A retrospective cohort study on a novel marker to predict the severity and prognosis of acute cerebral venous thrombosis: D-dimer to fibrinogen ratio [0.03%]
一种预测急性脑静脉血栓严重程度和预后的新型标志物的队列研究：D二聚体与纤维蛋白原比值
Duo Lan,Mengqi Wang,Xiaoming Zhang et al.
Duo Lan et al.
Background and aim: The D-dimer to fibrinogen ratio (DFR) represents an emerging and significant clinical biomarker. However, its correlation with cerebral venous thrombosis (CVT) remains underexplored. This retrospective...
Anticoagulation control for nonvalvular atrial fibrillation in a tertiary academic centre in Johannesburg [0.03%]
约翰内斯堡一家三级学术中心非瓣膜性房颤的抗凝控制
Vanessa Mogashoa,Dineo Mpanya,Nqoba Tsabedze
Vanessa Mogashoa
Background: Atrial fibrillation is a growing epidemic in Africa. Anticoagulation, considered the backbone for non-valvular atrial fibrillation (NVAF) management, is limited to warfarin as the mainstay of available anticoa...
Bleeding complications following intramuscular injections among hospitalized anticoagulated patients: a retrospective observational comparative study [0.03%]
住院抗凝患者的肌肉注射后出血并发症：一项回顾性观察性比较研究
Marina Davidov,Ronen Loebstein,Hagith Yonath et al.
Marina Davidov et al.
Background: Bleeding complications following intramuscular (IM) injections are generally considered rare with reported incidence of 0.06%. However, evidence on safety of IM injections among anticoagulated hospitalized pat...
Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial [0.03%]
补体抑制剂拉珠利单抗治疗成人血栓性微血管疾病患者后2周血小板计数变化与临床结局的关系：ANNIE研究的事后分析
Masanori Matsumoto,Akihiko Shimono,Jun Yokosawa et al.
Masanori Matsumoto et al.
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease with poor outcomes when untreated, in which ravulizumab or eculizumab are the standard of care where available. It has been proposed to regularly mon...
Synergistic effects of rivaroxaban and hypothermia or acidosis on coagulation initiation measured with ROTEM®: a prospective observational study [0.03%]
一项前瞻性观察性研究：使用ROTEM测量利伐沙班与低温或酸中毒对凝血启动的协同作用的效果
Lotta Sunnersjö,Isak Ymén,Ulf Schött et al.
Lotta Sunnersjö et al.
Background: Hypothermia and acidosis individually inhibit haemostasis. We designed this study with the aim to investigate whether rivaroxaban combined with hypothermia or acidosis exhibit synergistic inhibitory effects on...
Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review [0.03%]
替格瑞洛在ST段抬高型心肌梗死溶栓围期的作用：综述
Junyan Zhang,Lingya Li,Zhongxiu Chen et al.
Junyan Zhang et al.
Recent years have seen ticagrelor, a potent P2Y12 inhibitor, emerge as a significant advancement in the peri-thrombolytic management of patients with ST-segment elevation myocardial infarction (STEMI), offering a promising alternative to tr...